-
1
-
-
78651488228
-
-
Pharmaceutical Pricing Section, Pharmaceutical Benefits Branch, Government of Australia. Available from [ccessed 2006Jan 30]
-
Pharmaceutical Pricing Section, Pharmaceutical Benefits Branch, Ministry of Health and Ageing, Government of Australia. Expenditure and prescriptions twelve months to 30 June 2005 [online]. Available from URL: http://www.health. gov.au/internet/wcms/publishing.nsf/ Content/pbs-stats-pbexp-jun05-index [ccessed 2006Jan 30]
-
Expenditure and Prescriptions Twelve Months to 30 June 2005 [Online]
-
-
-
2
-
-
0037031061
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial
-
Heart Protection Study Collaborative Group
-
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
-
(2002)
Lancet
, vol.360
, pp. 7-22
-
-
-
3
-
-
4344683381
-
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial
-
Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96
-
(2004)
Lancet
, vol.364
, pp. 685-696
-
-
Colhoun, H.M.1
Betteridge, D.J.2
Durrington, P.N.3
-
4
-
-
11144355354
-
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
-
Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504
-
(2004)
N Engl J Med
, vol.350
, pp. 1495-1504
-
-
Cannon, C.P.1
Braunwald, E.2
McCabe, C.H.3
-
5
-
-
0036163750
-
FDA adverse event reports on statin-associated rhabdomyolysis
-
Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-95
-
(2002)
Ann Pharmacother
, vol.36
, pp. 288-295
-
-
Omar, M.A.1
Wilson, J.P.2
-
7
-
-
0037429617
-
Risk for myopathy with statin therapy in high-risk patients
-
Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553-64
-
(2003)
Arch Intern Med
, vol.163
, pp. 553-564
-
-
Ballantyne, C.M.1
Corsini, A.2
Davidson, M.H.3
-
8
-
-
0036053033
-
Myopathy associated with HMG-CoA reductase inhibitors (statins): A series of 10 patients and review of the literature
-
McKelvie PA, Dennett X. Myopathy associated with HMG-CoA reductase inhibitors (statins): a series of 10 patients and review of the literature. J Clin Neuromuscular Dis 2002; 3: 143-8
-
(2002)
J Clin Neuromuscular Dis
, vol.3
, pp. 143-148
-
-
McKelvie, P.A.1
Dennett, X.2
-
9
-
-
0036047090
-
HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions
-
Huynh T, Cordato D, Yang F, et al. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J 2002; 32: 486-90
-
(2002)
Intern Med J
, vol.32
, pp. 486-490
-
-
Huynh, T.1
Cordato, D.2
Yang, F.3
-
13
-
-
0032547751
-
The short life and rapid death of a novel antihypertensive and antianginal agent
-
Krum H, McNeil JJ. The short life and rapid death of a novel antihypertensive and antianginal agent. Med J Aust 1998; 169: 408-9
-
(1998)
Med J Aust
, vol.169
, pp. 408-409
-
-
Krum, H.1
McNeil, J.J.2
-
14
-
-
0031060641
-
Colchicine biotransformation by human liver microsomes: Identification of CYP3A4 as the major isoform responsible for colchicine demethylation
-
Tateishi T, Soucek P, Caraco Y, et al. Colchicine biotransformation by human liver microsomes: identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem Pharmacol 1997; 53: 111-6
-
(1997)
Biochem Pharmacol
, vol.53
, pp. 111-116
-
-
Tateishi, T.1
Soucek, P.2
Caraco, Y.3
-
16
-
-
27944470435
-
Rhabdomyolysis: An evaluation of 475 hospitalized patients
-
Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine 2005; 84: 377-85
-
(2005)
Medicine
, vol.84
, pp. 377-385
-
-
Melli, G.1
Chaudhry, V.2
Cornblath, D.R.3
-
17
-
-
0036091102
-
Colchicine-induced rhabdomyolysis
-
Boomershine KH. Colchicine-induced rhabdomyolysis. Ann Pharmacother 2002; 36 (5): 824-6
-
(2002)
Ann Pharmacother
, vol.36
, Issue.5
, pp. 824-826
-
-
Boomershine, K.H.1
-
18
-
-
0038147266
-
Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction
-
Sipe BE, Jones RJ, Bokhart GH. Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction. Ann Pharmacother 2003; 37: 808-11
-
(2003)
Ann Pharmacother
, vol.37
, pp. 808-811
-
-
Sipe, B.E.1
Jones, R.J.2
Bokhart, G.H.3
-
19
-
-
33845484201
-
Clopidogrel (Plavix): Suspected drug interaction with atorvastatin (Lipitor) and cyclosporine resulting in rhabdomyolysis
-
[online] Available from [Accessed 2006 Sep 19]
-
Canadian Adverse Reaction Newsletter. Clopidogrel (Plavix): suspected drug interaction with atorvastatin (Lipitor) and cyclosporine resulting in rhabdomyolysis [online]. Available from URL: http://www.hc-sc.gc.ca/dhp-mps/ medeff/bulletin/carn-bcei_v15n2_e.html [Accessed 2006 Sep 19]
-
Canadian Adverse Reaction Newsletter
-
-
-
20
-
-
0033406334
-
Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin
-
Mogyorósi A, Bradley B, Showalter A, et al. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J Intern Med 1999; 246: 599-602
-
(1999)
J Intern Med
, vol.246
, pp. 599-602
-
-
Mogyorósi, A.1
Bradley, B.2
Showalter, A.3
-
21
-
-
0031657436
-
Rhabdomyolysis after correction of hyponatremia due to psychogenic polydipsia possibly complicated by clozapine
-
Wicki J, Rutschmann OT, Burri H, et al. Rhabdomyolysis after correction of hyponatremia due to psychogenic polydipsia possibly complicated by clozapine. Ann Pharmacother 1998; 32: 892-5
-
(1998)
Ann Pharmacother
, vol.32
, pp. 892-895
-
-
Wicki, J.1
Rutschmann, O.T.2
Burri, H.3
-
22
-
-
14944369588
-
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy
-
Rätz Bravo AE, Tchambaz L, Krähenbühl-Melcher A, et al. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005; 28: 263-75
-
(2005)
Drug Saf
, vol.28
, pp. 263-275
-
-
Rätz Bravo, A.E.1
Tchambaz, L.2
Krähenbühl-Melcher, A.3
-
23
-
-
33845488099
-
-
Pharmaceutical Benefits Scheme [Online]. Available from [Accessed 2006 Jan 31]
-
Pharmaceutical Benefits Scheme, Medicare Australia [online]. Available from URL: http://www.medicareaustralia.gov.au/statistics/dyn_pbs/forms/pbs_tab1. shtml [Accessed 2006 Jan 31]
-
-
-
-
24
-
-
0034887738
-
Lipid-lowering drugs and risk of myopathy: A population-based follow-up study
-
Gaist D, García Rodríguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001; 12: 565-9
-
(2001)
Epidemiology
, vol.12
, pp. 565-569
-
-
Gaist, D.1
García Rodríguez, L.A.2
Huerta, C.3
-
25
-
-
9644252909
-
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
-
Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-90
-
(2004)
JAMA
, vol.292
, pp. 2585-2590
-
-
Graham, D.J.1
Staffa, J.A.2
Shatin, D.3
-
26
-
-
33645875021
-
Statin safety: An assessment using an administrative claims database
-
Cziraky MJ, Willey MJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006; Suppl. 97: 61C-8C
-
(2006)
Am J Cardiol
, vol.97
, Issue.SUPPL.
-
-
Cziraky, M.J.1
Willey, M.J.2
McKenney, J.M.3
-
27
-
-
4544243333
-
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes
-
de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. JAMA 2004; 292: 1307-16
-
(2004)
JAMA
, vol.292
, pp. 1307-1316
-
-
De Lemos, J.A.1
Blazing, M.A.2
Wiviott, S.D.3
-
28
-
-
24144437144
-
Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: The CAPISH Study
-
Krasuski RA, Doeppenschmidt D, Henry JS, et al. Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: The CAPISH Study. Mayo Clin Proc 2005; 80: 1163-8
-
(2005)
Mayo Clin Proc
, vol.80
, pp. 1163-1168
-
-
Krasuski, R.A.1
Doeppenschmidt, D.2
Henry, J.S.3
|